Other · 2026
A review of the case for and against psychedelic therapy for postpartum depression
- Original title
- Psychedelic therapy and postpartum depression: priorities and prospects.
- Authors
- Thuery G, Crossen F, Mc Loone D, et al.
- Journal
- Therapeutic advances in psychopharmacology, 2026
- Molecules
- Other
- Conditions
- Postpartum depression, Depression
- Evidence grade
- Very low
- Source
- Read the original paper
The question
Could serotonergic psychedelics (drugs such as classic psychedelics that act on serotonin receptors) be a reasonable treatment to study for postpartum depression, and what would need to be in place first?
What they did
The authors wrote a review rather than running a trial. They summarized what is known about the immune, hormonal and brain pathways involved in postpartum depression. They then discussed how serotonergic psychedelics interact with those same pathways, including in relation to maternal motivation, bonding and caregiving. They finished by outlining special safety considerations for the postpartum period and directions for future research.
What they found
The review notes that about 15% of pregnant women experience postpartum depression, and that many women remain impaired by symptoms even with existing antidepressant treatments. The authors report that early results from current trials suggest serotonergic psychedelics may be a viable approach, and that there is a biological rationale linking these drugs to pathways involved in postpartum depression. They also state that responses to psychedelic therapy vary markedly between people, and that the balance of benefit and risk in this specific population is not yet clear. Their conclusion is that further research is needed to establish both effectiveness and safety.
The fine print
This is a narrative review, so it does not test anything or pool results from trials, and no participant numbers or effect sizes are given. It reflects the authors’ selection and interpretation of the literature. The postpartum period raises specific issues, including breastfeeding and infant care, that the abstract flags as unresolved. This summary is based on the abstract only.
What it means
Researchers argue there is a plausible biological rationale for testing psychedelic therapy in postpartum depression, but they are explicit that effectiveness and safety in new mothers have not yet been established.
Evidence grade: Very low. This is a narrative review of existing theory and early findings, not a new study with participants or pooled data.
This summary is based on the study’s published abstract.